Abstract:Esophageal cancer (EC) is one of the most life-threatening malignancies worldwide. Esophageal squamous cell carcinoma (ESCC) is the dominant subtype, accounting for approximately 90% of new incident EC each year. Although multidisciplinary treatment strategies have advanced rapidly, patients with ESCC are often diagnosed at advanced stage and the long-term prognosis remains unsatisfactory. In recent decades, immunotherapy, such as immune checkpoint inhibitors (ICIs), tumor vaccines, and chimeric antigen receptor T-cell (CAR-T) therapy, has been successfully used in clinical practice as a novel therapy for treating tumors, bringing new hope to ESCC patients. However, only a small fraction of patients achieved clinical benefits due to primary or acquired resistance. Immune evasion plays a pivotal role in the initiation and progression of ESCC. Therefore, a thorough understanding of the mechanisms by which ESCC cells escape from anti-tumor immunity is necessary for a more effective multidisciplinary treatment strategy. It has been widely recognized that immune evasion is closely associated with the crosstalk between tumor cells and the tumor microenvironment (TME). TME is a dynamic complex and comprehensive system including not only cellular components but also non-cellular components, which influence hallmarks and fates of tumor cells from the outside. Novel immunotherapy targeting tumor-favorable TME represents a promising strategy to achieve better therapeutic responses for patients with ESCC. In this review, we provide an overview of immune evasion in ESCC, mainly focusing on the molecular mechanisms that underlie the role of TME in immune evasion of ESCC. In addition, we also discuss the challenges and opportunities of precision therapy for ESCC by targeting TME.

Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy Resistance

Tumor Immune Checkpoints and Their Associated Inhibitors

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies

Engineering Chimeric Antigen Receptor-T Cells for Cancer Treatment

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Strategies for Overcoming Immune Evasion in Bladder Cancer

Overcoming Immune Evasion in T Cell Therapy of Cancer: Lessons from Animal Models

Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies

Targeting the Immune-Suppressive Tumor Microenvironment to Potentiate CAR T Cell Therapy

Immune evasion by cancer stem cells

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in Non-Small-Cell Lung Carcinoma

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

Clinical Status, Drug Resistance, and Countermeasures of CAR-T Cell Cancer Immunotherapy

Strategies for Dodging the Obstacles in CAR T Cell Therapy

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Immunological hide-and-seek: epigenetically reprogrammed cancer cells and the dynamics of CD8+ T cells

Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment